Thomas Lobl

Dr. Thomas Lobl holds a Ph.D. from Johns Hopkins University and did post-graduate work at Caltech and Rockefeller University. He has worked in the pharmaceutical industry for over four decades in both the big pharma and biotech industries. In 2002, he joined the Al Mann family of companies at AlleCure/Mannkind as Vice-President of Research and Development and was subsequently promoted to Senior Vice-President of R&D.

In January 2004, he helped start NeuroSystec, an Alfred Mann-funded company. NeuroSystec devised a therapy to inhibit the spontaneous firing of the spiral ganglion for the treatment of tinnitus, and auditory dysfunction that affects more than 50 million people in the US alone. Dr. Lobl served as acting CEO of the company for nearly seven years.

From October 2011 until October 2015, Dr. Lobl worked as an Emerging Technology Strategist at the Alfred Mann Foundation. In November of 2015, he began working at the Alfred Mann Institute at USC as an Entrepreneur in Residence and as a consultant.